• Successful $5.5m placement and $7m Share Purchase Plan
• 265.3% increase in operating revenue to $3.8m
• Gross margin stable at over 90%

4DMedical Limited (ASX:4DX) has reported its half-year results for the period ended 31 December 2024 (1H FY25). The company received strong support from new and existing institutional investors for a $5.5 million placement, and also launched a $7 million Share Purchase Plan. Operating revenue increased by 265.3% to $3.8 million, driven by Software-as-a-Service (SaaS) contracts, with gross margin remaining stable at over 90%. 4DMedical delivered over 8,000 scans in 1H FY25, up 37% from 2H FY24 and 77% on the prior corresponding period, and is now operating at 301 sites globally, up 24% from 2H FY24 and 41% on pcp. The company made significant progress in commercialisation, signing key reference sites in the U.S. and Australia, and received FDA clearance for its IQ-UIP product. 4DMedical also presented clinical trial data for its CT:VQ technology at RSNA 2024 and secured $1.9 million in CRC-P funding to accelerate the generation of clinical evidence. The group's net cash balance was $16.0 million as at 31 December 2024.